Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 54,906 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107
View directory record Official record
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 3:37 AM EDT
Completed No phase listed Observational

Multi-Center Study on Performance of the Ponto Implant System Using Minimally Invasive Ponto Surgery (in Adult Patients)

NCT04279236
View directory record Official record
Conditions
Hearing Loss
Interventions
Abbreviated Profile Hearing Aid Benefit (APHAB), Glasgow Benefit Inventory (GBI), Additional follow-up visit
Other
Lead sponsor
Oticon Medical
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Sarasota, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 31, 2026, 3:37 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

NCT02287311
View directory record Official record
Conditions
Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor
Interventions
MABEL CTLs, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 4 Interventional

Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

NCT01170611
View directory record Official record
Conditions
Sinus Node Dysfunction, Brady Tachy Syndrome
Interventions
PACEMAKER SYMPHONY 2550
Device
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02101944
View directory record Official record
Conditions
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 31, 2026, 3:37 AM EDT
Not listed No phase listed Observational

Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

NCT03243864
View directory record Official record
Conditions
Renal Failure, Bacterial Infections, Critical Illness
Interventions
Ceftazidime-avibactam
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study on the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression

NCT00703209
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Nerve Decompression
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

NCT01470599
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 76 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
32
States / cities
Oceanside, California • Lafayette, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma

NCT03451799
View directory record Official record
Conditions
GBM, Glioblastoma
Interventions
Ketogenic Diet, Standard-of-care radiation, Standard-of-care Temozolomide
Other · Radiation · Drug
Lead sponsor
Jethro Hu
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

NCT00076999
View directory record Official record
Conditions
HIV Infections
Interventions
TPV oral solution, RTV oral solution
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 18 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 2 Interventional

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

NCT00004163
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
10
States / cities
New Haven, Connecticut • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Not applicable Interventional

Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

NCT05304793
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Best Practice, Cognitive Behavior Therapy, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

NCT00024284
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, irinotecan hydrochloride
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
6
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT02909452
View directory record Official record
Conditions
Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions
Entinostat, Pembrolizumab
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

NCT00002752
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 31, 2026, 3:37 AM EDT
Not yet recruiting Not applicable Interventional

The AYA Oncology Self-care Movement

NCT07724652
View directory record Official record
Conditions
Acute Lymphobkastic Leukemia, Medication Adherence
Interventions
Educational Website, #AYAOSM
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
15 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 3:37 AM EDT
No Longer Available No phase listed Expanded access

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

NCT01701947
View directory record Official record
Conditions
Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
Interventions
Hemoleven
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months and older
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 31, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

NCT05211947
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 51 Years
Enrollment
1,356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
49
States / cities
Anaheim, California • Bellflower, California • Culver City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Phase 4 Interventional

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Atorvastatin calcium, Inactive Placebo
Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
25 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 31, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

NCT01507155
View directory record Official record
Conditions
Treatment Resistant Depression, Generalized Anxiety Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chalfont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 31, 2026, 3:37 AM EDT